Merck & Co, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Vanguard Capital Management disclosed a beneficial ownership of 186,323,766 shares, representing 7.53% of Merck & Co.'s common stock as of March 31, 2026.
NYSE
The Vanguard Group has reported 0% beneficial ownership of Merck & Co Inc common stock following an internal realignment on January 12, 2026.
NYSE
The Vanguard Group has filed an amended Schedule 13G, disclosing a beneficial ownership of 10.02% in Merck & Co Inc's common stock as of February 28, 2025.
NYSE
SCHEDULE 13G/A: Merck & Co. Affirms Nearly 20% Stake in Evaxion Biotech A/S Through Subsidiary Holdings
Merck & Co., through its indirect wholly-owned subsidiary Merck Global Health Innovation Fund, LLC, has reported a beneficial ownership of 19.96% in Evaxion Biotech A/S, comprising ordinary shares and warrants.